CClinicalTrials.gg
Sign In
CompletedNCT02311387Updated Dec 12, 2019

Seroprevalence and Incidence of Lassa Fever in the Rural Commune of Sibirila, District of Bougouni, Mali

An observational study in Lassa Virus Infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID). Completed at 1 site in Mali. Open to participants aged 6 Months and older. Per ClinicalTrials.gov, last updated 2019-12-12.

Sponsored by National Institute of Allergy and Infectious Diseases (NIAID) · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
601
Ages
6 Months and older
Sex
All
01

Study summary

Background:

  • Lassa fever is very similar to other diseases that cause fever, such as malaria and yellow fever. People get Lassa fever from mice. A person can get Lassa fever from mice urine and droppings. When a group of researchers tested the mice in Soromba, Mali, they found that many were infected with Lassa fever. Lassa fever may also be passed through body fluids (like blood or semen) of people infected with Lassa fever. Researchers want to study this disease to help the government better protect the health of people in Sibirila.

Objectives:

  • To find out how many people in Sibirila have ever had Lassa fever. Also, to measure how many people get the disease every year.

Eligibility:

  • People age 6 months and older who are residents of Soromba, Bamba, or Banzana with no plans to relocate within 1 year.

Design:

  • Households will be randomly selected to participate in the study.
  • Participants will have up to 20 drops of blood collected from the finger or heel.
  • Participants will be asked about their age. They will be asked if they have ever had a fever and if they have ever seen mice in or around their home.
  • Researchers will come back in 1 year and take another drop of blood from the participant. Participants will be asked the same questions.
  • If a participant has a fever at any time during the year, he or she should go to the health center. Researchers

will collect a few drops of blood to test for Lassa fever.

...

Read the detailed description

Throughout West Africa as many as 300,000 people are infected annually with Lassa virus, resulting in approximately 5,000 deaths. Most commonly, contact with infected rodent hosts (Mastomys natalensis), or ingestion / inhalation of virus laden particles is the source of human infection. However, person-to-person transmission is also well documented and can result in outbreaks, especially in nosocomial settings. Infection in pregnancy, especially the third trimester, is particularly severe with maternal mortality rates estimated at 20% and fetal mortality rates nearing 100%. A survey of rodents captured in the village of Soromba (rural commune of Sibirila, district of Bougouni, Mali) found that 25% of Mastomys natalensis had evidence of Lassa virus infection.

The purpose of this study is to determine the proportion of people who have been previously exposed to Lassa virus, as well as the one-year incidence of infection in three villages within the rural commune of Sibirila, district of Bougouni. We will obtain 2 fingerstick blood samples (approximately one year apart) from each of approximately 600 participants aged greater than or equal to 6 months. Participants will be passively followed for one year and asked to present to their local health center if they have a fever.

Elucidation of the prevalence of Lassa virus infection in the populations living in or near Sibirila may help Malian authorities to improve surveillance and/or local diagnostics. Accurate identification of Lassa virus infections in humans will help reduce the morbidity and mortality of those living in this area.

The incidence and etiology of vector-borne diseases in southern Mali is relatively unknown. It is possible to use these samples to screen for other vector-borne diseases using similar serological assays. Expanding the testing to include filoviruses, bunyaviruses, alphaviruses and flaviviruses would greatly benefit our knowledge of circulating pathogens in southern Mali as well as the public health by helping to reduce the morbidity and mortality of those living in the area.

02

Conditions studied

  • Lassa Virus Infection

Keywords

  • Incidence
  • Prevalence
  • Human
  • Mastomys
  • Serosurvey
03

In context

Lead sponsor

National Institute of Allergy and Infectious Diseases (NIAID) is the lead sponsor of 2,401 studies on the registry; 179 are open to participants now.

Of its 396 completed or terminated interventional studies of FDA-regulated products, 294 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Age greater than or equal to 6 months.
  • Resident of Soromba, Bamba or Banzana with no plans to relocate within 1 year.

Exclusion criteria

EXCLUSION CRITERIA:

  • Any condition that in the opinion of the investigator would render the participant unable to comply with the protocol (e.g., psychiatric disease).
  • Any health condition that would confound data analysis or pose unnecessary exposure risks to study personnel in the opinion of the investigator.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
601 participants (actual)
06

What researchers measure

Primary outcomes

  1. To determine the seroprevalence of Lassa virus infection in the population of Southern Mali at the study start date. The prevalence of Lassa virus infection will be based on serological evidence in the villages of Soromba, Bamba and Banzana.

    Time frame: At time of study start.

  2. To determine the proportion of individuals in these villages who haveexperienced symptoms consistent with Lassa fever at the start of the study

    Time frame: At time of study start.

  3. To determine the annual incidence of seroconversion due to Lassa virus infection. Prevalence of Lassa virus exposure at the start of the study will be compared to the prevalence at the end of one calendar year to determine the one year incidence...

    Time frame: One year after study start date.

07

Study locations

1 site
  • Malaria Research and Training Center
    Bamako, Mali
08

References and documents

Publications

  • Atkin S, Anaraki S, Gothard P, Walsh A, Brown D, Gopal R, Hand J, Morgan D. The first case of Lassa fever imported from Mali to the United Kingdom, February 2009. Euro Surveill. 2009 Mar 12;14(10):19145. PubMed 19317988 ↗
  • Safronetz D, Sogoba N, Lopez JE, Maiga O, Dahlstrom E, Zivcec M, Feldmann F, Haddock E, Fischer RJ, Anderson JM, Munster VJ, Branco L, Garry R, Porcella SF, Schwan TG, Feldmann H. Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali. PLoS Negl Trop Dis. 2013 Dec 5;7(12):e2582. doi: 10.1371/journal.pntd.0002582. eCollection 2013. PubMed 24340119 ↗
  • Sogoba N, Feldmann H, Safronetz D. Lassa fever in West Africa: evidence for an expanded region of endemicity. Zoonoses Public Health. 2012 Sep;59 Suppl 2:43-7. doi: 10.1111/j.1863-2378.2012.01469.x. PubMed 22958249 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02311387
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Responsible party
Sponsor
First posted
Dec 8, 2014
Start date
Dec 5, 2014
Primary completion
Oct 31, 2016
Completion
Oct 22, 2018
Last update
Dec 12, 2019

Study contacts

Heinrich U Feldmann, M.D.
principal investigator · National Institute of Allergy and Infectious Diseases (NIAID)
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Lassa Fever

Other studies from this sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Start the discussion